World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 2 November 2015
Main ID:  NCT02258880
Date of registration: 29/09/2014
Prospective Registration: No
Primary sponsor: Daiichi Sankyo Inc.
Public title: Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
Scientific title: A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Date of first enrolment: September 2014
Target sample size: 0
Recruitment status: Withdrawn
URL:  https://clinicaltrials.gov/show/NCT02258880
Study type:  Interventional
Study design:  Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment  
Phase:  Phase 2
Countries of recruitment
Canada Israel South Africa United States
Contacts
Name:     Ger Rikken, MD
Address: 
Telephone:
Email:
Affiliation:  Asubio Pharmaceuticals, Inc.
Key inclusion & exclusion criteria

Each subject must meet all of the following criteria to participate in the study:

1. Male or female subjects between 18 and 85 years, inclusive

2. Subjects with no prior history of stroke (unless the stroke was not associated with a
motor deficit)

3. Subjects must score at least 16 points on the standard MMSE during baseline
assessments

4. Subjects must have a total score between 7 and 30, inclusive, out of 35 on the
S-STREAM administered between 24 and 48 hours after the onset of acute stroke

5. Subjects must have an estimated pre-stroke mRS of 0 or 1

6. Male subjects agree to be heterosexually abstinent or use appropriate contraception

7. Female subjects must have undergone menopause or, if premenopausal, must have a
negative pregnancy test at baseline. Female subjects of childbearing potential agree
to be sexually abstinent or must be willing to utilize adequate contraception

8. Subjects must be willing to provide verbal/nonverbal informed consent indicating
voluntary consent to participate in the study (if a subject is unable to provide
informed consent, but able to comply with other study procedures, the subject's LAR
may provide consent)

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study:

1. Prior exposure to SUN13837

2. History of severe allergic reaction, whether explained or not, requiring a visit to
the ER and/or medical intervention with epinephrine

3. Development of hemodynamic instability following the acute stroke

4. History of dementia, advanced Parkinson's disease, other significant movement
disorders, or other clinically significant diseases which would jeopardize the safety
of the subject or impact the validity of the study results

5. Presence of significant global or receptive aphasia

6. Presence of clinically significant abnormal laboratory values at the time of
presentation in the ER

7. History of malabsorption or any gastrointestinal abnormality that could impair oral
absorption

8. Finding of Grade 3 or 4 proliferative retinopathy on routine fundoscopic examination
or history of proliferative retinopathy (Grade 3 or 4) in subjects with diabetes
mellitus

9. Unable, as determined by the investigator, or unwilling to discontinue use of potent
cytochrome (CYP) P450 3A4/5 inhibitors, potent CYP2D6 inhibitors, CYP3A inducers, or
potent P glycoprotein (P gp) inhibitors

10. Current participation in another clinical study involving administration of an
investigational product or history of such participation within 30 days of acute
stroke onset



Age minimum: 18 Years
Age maximum: 85 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Stroke
Intervention(s)
Drug: placebo
Drug: SUN13837
Primary Outcome(s)
Mean change from baseline in the Physical Performance Assessment in Stroke (PPAS) [Time Frame: 84 days]
Secondary Outcome(s)
Mean change from baseline in Short Form-36 Physical Functioning Scale (SF-36 PF) [Time Frame: 84 days]
Mean change from baseline in PPAS Patient Reported Outcome Subscale [Time Frame: 84 days]
Mean change from baseline in Gait Speed [Time Frame: 84 days]
Proportion of responders as measured by the Modified Rankin Scale (mRS) [Time Frame: 84 days]
Safety/Tolerability - Number of Participants with Adverse Events [Time Frame: 84 days]
The proportion of responders as measured by the PPAS [Time Frame: 84 days]
Secondary ID(s)
ASBI 802
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
INC Research
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history